Alix Debrogniez

Learn More
Previous attempts to produce a vaccine against BLV faced problems of efficacy (i.e. only a fraction of animals were protected), persistence (i.e. rapid decrease of immune protection), cost (e.g. production of purified proteins) or safety (e.g. genetically modified hybrid viruses). We have designed a novel strategy based on the use of a live-attenuated BLV(More)
There is a long lasting debate about the latency of human T-lymphotropic virus type 1 (HTLV-1) and bovine leukemia virus (BLV). Evidence indicates that these viruses are transcriptionally silent and replicate through mitotic division of infected cells (clonal expansion). However, this model is inconsistent with the permanent and vigorous stimulation of the(More)
  • 1